Trial NCT03481556

View at ClinicalTrials.gov 
Org. Study IDs: OP-104

Last trial update was posted on 2022-12-19

MeSH Interventions

Bortezomib Daratumumab Dexamethasone Dexamethasone acetate Melphalan

MeSH Conditions

Multiple Myeloma Neoplasms, Plasma Cell

Other Conditions


Stopping Reasons

The sponsor decided to terminate the study following an FDA request of a partial clinical hold.

Limitations And Caveats

On 04 November 2021, the study was terminated early during Phase 2a.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID